
Last updated: 2026-09-04 16:59:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Jyong Biotech Ltd. (MENS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.35, with a market capitalization of $167.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.43 to $67.00. This page covers its latest market performance, valuation, price trends and company information.
$167.03M | |
$2.32 | |
$67.00 | |
$1.43 | |
$2.27 | |
20.70K | |
-- | |
-- | |
$67.00 | |
$1.43 | |
-- | |
-- |
Jyong Biotech Ltd. (MENS) is currently trading at $2.35 as of 2026-09-04 16:49:00, up 3.57% ($0.08) from the previous close of $2.27
During today's regular trading session, MENS has traded between $1.43 and $67.00, with a trading volume of 20.70K shares. The current price is near the lower end of today's range.
Over the past seven days, Jyong Biotech Ltd. (MENS) moved from $2.40 to $2.35, representing a decline of 2.04% ($0.05).
The stock traded between $2.31 and $2.43 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 30.40 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.4%
MENS is currently trading at $2.35, placing it 1.4% of the way from its 52-week low of $1.43 to its 52-week high of $67.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
| Employees | 27 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jyong Biotech Ltd. (MENS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.